Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. GOOGL
6. APGE
7. MU
8. DFTX
9. HOOD
10. RGNX

Go back to Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
(NASDAQ: KURA) Delayed: 10.33 +0.40 (4.03%)
Previous Close $9.93    52 Week High $8.90 
Open $9.96    52 Week Low $2.50 
Day High $10.54    P/E N/A 
Day Low $9.95    EPS $0.00 
Volume 901,488